<DOC>
	<DOCNO>NCT00738673</DOCNO>
	<brief_summary>This open-label , multi-centre , uncontrolled , exploratory trial duration 12 month two cohort . The trial aim investigate Degarelix second-line hormonal treatment Prostate Cancer patient experience PSA-Failure follow gonadotropin-releasing hormone ( GnRH ) agonist treatment . The two cohort differ Testosterone level inclusion .</brief_summary>
	<brief_title>Degarelix Second-Line Hormonal Treatment After Prostate-specific Antigen ( PSA ) -Failure GnRH Agonist Treated Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<criteria>Patient give write informed consent trialrelated activity perform . Patient 18 year old . Histologically confirm prostate cancer . Patient receive GnRH receptor agonist therapy duration least 12 month ( first dose GnRHantagonist administer next dose GnRHagonist would due ) . Patient experience rise PSA level although receive GnRH agonist therapy , define two consecutive rise PSA least two week apart two 50 % increase nadir , least one PSA value &gt; 2.5 ng/mL within last six month . Testosterone castrate level ( define ≤ 0.5 ng/mL ) ( cohort 1 ) ; Testosterone ≥0.2 ng/mL inclusion ( cohort 2 ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . Estimated life expectancy least 12 month . Previous history presence another malignancy , prostate cancer treat squamous / basal cell carcinoma skin , within last five year . Ongoing GnRH agonist therapy ( last dose previous GnRH agonist must receive Visit 1 ) . Any pretrial secondary hormonal manipulation ( include antiandrogens ) PSA increase describe trial entry . Antiandrogens part complete androgen blockade must discontinue least three month first dose trial medication . Previous current treatment chemotherapy ( e.g . estramustine ) prostate cancer . Known hypersensitivity towards component investigational medical product . History severe uncontrolled asthma , anaphylactic reaction , severe urticaria and/or angioedema . Known suspect clinically significant liver and/or biliary disease . Any clinically significant laboratory abnormality , disorder , condition , include alcohol drug abuse , may affect patient 's health outcome trial judge Investigator . Patient clinically significant disorder ( prostate cancer ) include , limited , renal , hematological , gastrointestinal , endocrine , cardiac , neurological , psychiatric disease , alcohol drug abuse condition , may affect patient 's health outcome trial judge Investigator . Patient mental incapacity language barrier preclude adequate understanding cooperation . Patient receive investigational drug within last 28 day precede screen visit . Or long consider possibly influence outcome current trial . Previous participation degarelix trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Hormone refractory prostate cancer</keyword>
	<keyword>Agonist treatment failure</keyword>
</DOC>